BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ruffolo LI, Jackson KM, Kuhlers PC, Dale BS, Figueroa Guilliani NM, Ullman NA, Burchard PR, Qin SS, Juviler PG, Keilson JM, Morrison AB, Georger M, Jewell R, Calvi LM, Nywening TM, O'Dell MR, Hezel AF, De Las Casas L, Lesinski GB, Yeh JJ, Hernandez-Alejandro R, Belt BA, Linehan DC. GM-CSF drives myelopoiesis, recruitment and polarisation of tumour-associated macrophages in cholangiocarcinoma and systemic blockade facilitates antitumour immunity. Gut 2022;71:1386-98. [PMID: 34413131 DOI: 10.1136/gutjnl-2021-324109] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhu D, Shi X, Tian Y, Li H, Tang B, Zhang Z, Zhang Z, Zuo L. Combining expression of RNF43 and infiltration level of CD163+ tumor associated macrophage predicts prognosis of clear cell renal cell carcinoma. Cancer Med 2022. [PMID: 36097369 DOI: 10.1002/cam4.5229] [Reference Citation Analysis]
2 Lin Z, Huang Q, Liu J, Wang H, Zhang X, Zhu Z, Zhang W, Wei Y, Liu Z, Du W. Interleukin-17D promotes lung cancer progression by inducing tumor-associated macrophage infiltration via the p38 MAPK signaling pathway. Aging. [DOI: 10.18632/aging.204208] [Reference Citation Analysis]
3 Kumar A, Taghi Khani A, Sanchez Ortiz A, Swaminathan S. GM-CSF: A Double-Edged Sword in Cancer Immunotherapy. Front Immunol 2022;13:901277. [DOI: 10.3389/fimmu.2022.901277] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
4 Nie W, Chen J, Wang B, Gao X. Nonviral vector system for cancer immunogene therapy. MedComm – Biomaterials and Applications 2022;1:mba2.10. [DOI: 10.1002/mba2.10] [Reference Citation Analysis]